Non-Hodgkin’s Lymphoma (NHL)
RIABNI® (rituximab-arrx) is indicated for the treatment of adult patients with:
Chronic Lymphocytic Leukemia (CLL)
RIABNI®, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid Arthritis (RA)
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
RIABNI®, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
Benefits Verification
Prior Authorization Requirements
Amgen SupportPlus Customer Portal
Visit myAmgenPortal.com to register and submit forms online
Contact your Field Reimbursement Specialist for live or virtual support that includes:
*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/Copay for full Terms and Conditions.
Learn more about how Amgen SupportPlus can help your patients access their prescribed medication.
Call Amgen® SupportPlus at 866-264-2778 Monday - Friday 9:00 am – 8:00 pm ET to learn more.
†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.
Amgen Nurse Partners can provide support, including:
Patients can connect with an Amgen Nurse Partner by enrolling in Amgen SupportPlus in two ways:
‡Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
Resource Guide contains billing and coding information, supply, preparation and dosing information plus support services.
Call 866-264-2778
Monday through Friday - 9.00 AM to 8.00 PM ET
Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.
Obtain patient insurance coverage and cost information
Allows access specialist to provide case-specific support
Sample letter template that can be used to demonstrate medical necessity
Sample letter template that can be used if appealing a PA denial
Refer to this guide for billing and coding information as well as general information about how to use RIABNI®
Amgen has a sponsorship with National Infusion Center Association (NICA) to help your RIABNI® patients and your practice find alternative sites of care in your area
Simple educational content to help patients feel confident about receiving a biosimilar (based on FDA guidance)
Your patient's guide to understanding and starting treatment with RIABNI®
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.
RIABNI® (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI® is a registered trademark of Amgen Inc.
Truxima® is a registered trademark of Teva Pharmaceuticals.
Ruxience® is a trademark of Pfizer.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.
RIABNI® (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI® is a trademark of Amgen Inc.
Truxima® is a registered trademark of Teva Pharmaceuticals.
Ruxience™ is a trademark of Pfizer.